Abstract
Acalabrutinib is a next-generation, more selective, covalent Bruton tyrosine kinase inhibitor (BTKi), designed to have less toxicity, including bleedi......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
